FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377107882> ?p ?o ?g. }

• W4377107882 endingPage "100709" @default.
• W4377107882 startingPage "100709" @default.
• W4377107882 abstract "SSO2 is approved for infusion after primary PCI in non-shock LAD STEMI patients with symptom onset within 6 hours of presentation. However, data related to improvements in LVEF with SSO2 therapy in patients presenting late, after 6 hours of symptom onset, is scarce. Following primary PCI patients were treated with a 60 min infusion of hyperoxemic solution via a catheter placed in the left main ostium. Autologous blood was drawn from the femoral artery and mixed with normal saline in a proprietary high pressure mixing chamber (Zoll Inc., Chelmsford, MA) before being re-infused. All patients treated with SSO2 at our institution from June 2021 were included in analysis. Patients with LAD STEMI, without cardiogenic shock, and at least one month clinical/echo follow up were included. Absolute change in echo LVEF at one and three months were compared between SSO2 and contemporaneous control patients that underwent PCI without SSO2 infusion. For analysis we divided the SSO2 group into 2 sub-groups: patients with symptom onset within 6 hours of presentation and patients with symptom onset >6 hours. 34 patients aged 41 to 75years were included: n=20 received SSO2 and n=14 in the control group. The SSO2 group included 14 patients with symptom onset within 6 hours of presentation and 6 patients who presented later than 6 hours and had collateral circulation. No significant difference in baseline characteristics was observed between groups. Among patients with symptom onset within 6 hours there was a significant increase in LVEF at one month from baseline in the 14 patients treated with SSO2 (16.8%) vs control (3%) (p=0.003). Results were consistent at three months; 23% LVEF increase in SSO2 vs 5% in control (p<0.001). Patients in the SSO2 group with symptom onset >6 hours, experienced similar improvements in LVEF (15%) at one month from baseline compared to those observed in the SSO2 group who presented early (16.8%). Our results suggest that intracoronary SSO2 infusion following primary PCI for LAD STEMI results in improvements in LVEF compared to standard PCI alone, both in patients presenting within the currently approved 6-hour window of symptom onset as well as those patients who present late and have collateral circulation." @default.
• W4377107882 created "2023-05-20" @default.
• W4377107882 creator A5009886929 @default.
• W4377107882 creator A5015423546 @default.
• W4377107882 creator A5034478381 @default.
• W4377107882 creator A5040662112 @default.
• W4377107882 creator A5061144061 @default.
• W4377107882 creator A5073892710 @default.
• W4377107882 creator A5091982588 @default.
• W4377107882 date "2023-05-01" @default.
• W4377107882 modified "2023-09-27" @default.
• W4377107882 title "A-45 | SuperSaturated Oxygen Infusion Improves LV Function over PCI Alone Regardless of Time to Treatment: Retrospective, Single Center, Real World Comparison to Control Patients" @default.
• W4377107882 doi "https://doi.org/10.1016/j.jscai.2023.100709" @default.
• W4377107882 hasPublicationYear "2023" @default.
• W4377107882 type Work @default.
• W4377107882 citedByCount "0" @default.
• W4377107882 crossrefType "journal-article" @default.
• W4377107882 hasAuthorship W4377107882A5009886929 @default.
• W4377107882 hasAuthorship W4377107882A5015423546 @default.
• W4377107882 hasAuthorship W4377107882A5034478381 @default.
• W4377107882 hasAuthorship W4377107882A5040662112 @default.
• W4377107882 hasAuthorship W4377107882A5061144061 @default.
• W4377107882 hasAuthorship W4377107882A5073892710 @default.
• W4377107882 hasAuthorship W4377107882A5091982588 @default.
• W4377107882 hasBestOaLocation W43771078821 @default.
• W4377107882 hasConcept C126322002 @default.
• W4377107882 hasConcept C141071460 @default.
• W4377107882 hasConcept C164705383 @default.
• W4377107882 hasConcept C2776850375 @default.
• W4377107882 hasConcept C2778198053 @default.
• W4377107882 hasConcept C2780073493 @default.
• W4377107882 hasConcept C45393284 @default.
• W4377107882 hasConcept C500558357 @default.
• W4377107882 hasConcept C71924100 @default.
• W4377107882 hasConcept C78085059 @default.
• W4377107882 hasConceptScore W4377107882C126322002 @default.
• W4377107882 hasConceptScore W4377107882C141071460 @default.
• W4377107882 hasConceptScore W4377107882C164705383 @default.
• W4377107882 hasConceptScore W4377107882C2776850375 @default.
• W4377107882 hasConceptScore W4377107882C2778198053 @default.
• W4377107882 hasConceptScore W4377107882C2780073493 @default.
• W4377107882 hasConceptScore W4377107882C45393284 @default.
• W4377107882 hasConceptScore W4377107882C500558357 @default.
• W4377107882 hasConceptScore W4377107882C71924100 @default.
• W4377107882 hasConceptScore W4377107882C78085059 @default.
• W4377107882 hasIssue "3" @default.
• W4377107882 hasLocation W43771078821 @default.
• W4377107882 hasOpenAccess W4377107882 @default.
• W4377107882 hasPrimaryLocation W43771078821 @default.
• W4377107882 hasRelatedWork W106149517 @default.
• W4377107882 hasRelatedWork W2193765730 @default.
• W4377107882 hasRelatedWork W2347369427 @default.
• W4377107882 hasRelatedWork W2350089619 @default.
• W4377107882 hasRelatedWork W2359117289 @default.
• W4377107882 hasRelatedWork W2365255129 @default.
• W4377107882 hasRelatedWork W2368404399 @default.
• W4377107882 hasRelatedWork W2380772110 @default.
• W4377107882 hasRelatedWork W2390426451 @default.
• W4377107882 hasRelatedWork W2528284439 @default.
• W4377107882 hasVolume "2" @default.
• W4377107882 isParatext "false" @default.
• W4377107882 isRetracted "false" @default.
• W4377107882 workType "article" @default.